Article

Citizens' perspectives on personalized medicine: a qualitative public deliberation study.

Yale University, School of Public Health & Memorial Sloan-Kettering Cancer Center, Center for Health Policy and Outcomes and Clinical Genetics Service, New York, NY, USA.
European journal of human genetics: EJHG (Impact Factor: 4.23). 01/2013; DOI: 10.1038/ejhg.2012.300
Source: PubMed

ABSTRACT Our objective was to explore citizens' informed and reasoned values and expectations of personalized medicine, a timely yet novel genomics policy issue. A qualitative, public deliberation study was undertaken using a citizens' reference panel on health technologies, established to provide input to the health technology assessment process in Ontario, Canada. The citizens' panel consisted of five women and nine men, aged 18-71 years, with one member selected from each health authority region. There were shared expectations among the citizens' panel members for the potential of personalized medicine technologies to improve care, provided they are deemed clinically valid and effective. These expectations were tempered by concerns about value for money and the possibility that access to treatment may be limited by personalized medicine tests used to stratify patients. Although they questioned the presumed technological imperative presented by personalized medicine technologies, they called for increased efforts to prepare the health-care system to effectively integrate these technologies. This study represents an early but important effort to explore public values toward personalized medicine. This study also provides evidence of the public's ability to form coherent judgments about a new policy issue. Concerned that personalized tests might be used to ration care, they suggested that treatment should be made available if patients wanted it, irrespective of tests that indicate little benefit. This issue raises clinical and policy challenges that may undermine the value of personalized medicine. Further efforts to deliberate with the public are warranted to inform effective, efficient and equitable translation of personalized medicine.European Journal of Human Genetics advance online publication, 23 January 2013; doi:10.1038/ejhg.2012.300.

Full-text

Available from: Yvonne Bombard, Jun 07, 2015
1 Follower
 · 
113 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Personalized medicine is revolutionizing modern health care. The aim of personalized diagnostics is to provide rapid, portable and simple tests that will reduce diagnosis time. They enable rapid analysis performed near the patient and provide specific details of the patient’s condition so that a personalized treatment can be made. This review focuses on the recent advances in optical diagnostic techniques based on surface plasmon resonance (SPR) and surface-enhanced Raman scattering spectroscopy (SERS) for translational medical diagnostics. In the first part, recent developments in SPR biosensors for infectious disease diagnosis are presented including the first two-dimensional multiplex influenza SPR biosensor for H1N1 (influenza A) and H3N2 (seasonal influenza) detection. In the second part, advances in SERS, which is another ultra-sensitive optical diagnostic technique for various cancer detection applications in pre-clinical and clinical settings, are reviewed.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review Personalized medicine encompasses the use of biological information such as genomics to provide tailored interventions for patients. The review explores the ethical, legal, and social issues that have emerged with personalized medicine and must be considered because of the complex nature of providing individualized care within a clinical setting. Recent findings Recent studies found that the use of personalized medicine presents challenges in multiple areas: biobanking and informed consent, confidentiality, genetic discrimination, return of results, access to treatment, clinical translation, direct-to-consumer genetic testing, emerging duties, and knowledge mobilization. Summary Although personalized medicine provides benefits in treating patients in a manner that is more suited to their genetic profile, there are challenges that must be discussed to ensure the protection and fair treatment of individuals. The issues concerning personalized medicine are widespread, and range from individual privacy to the stratification and discrimination of sub-populations based on ethnicity. These issues have considerable impact on the individual and society. A thorough exploration of these ethical issues may identify novel challenges as well as potential avenues for resolution.
    Current Opinion in Allergy and Clinical Immunology 07/2014; 14(5). DOI:10.1097/ACI.0000000000000091 · 3.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients treated successfully for pediatric Hodgkin's lymphoma are known to develop secondary malignancies; care is already taken in treatment to prevent this adverse effect. Recent GWAS study identified rs4946728 and rs1040411 noncoding SNPs located between PRDM1 and ATG1 genes on chromosome 6q21 as risk factors for secondary malignancies in patients formerly treated with radiotherapy for pediatric Hodgkin disease. We investigated the allele frequencies of these two SNPs in biobanked, randomly selected DNA of average, apparently healthy Hungarians (n = 277) and in samples of Roma (n = 279) population living Hungary. The risk allele frequency for rs4946728 was 79.4 % in Hungarian and 83.5 % in Roma samples, while for rs1040411 it was 56.4 % in Hungarian and 55.8 % in Roma samples. These values are quite similar in the two populations, and are rather high. The values are higher than those frequencies observed in the controls (rs4946728: 59.1 % and rs1040411: 39.6 %, p < 0.05), and are in the range of the cases (86 % and 68.2 %, respectively) of the above original GWAS study. Our findings suggest, that beside the already taken precautions, genetic characterization of Hungarian pediatric Hodgkin patients seems to be advantageous prior to the treatment of their disease.
    Pathology & Oncology Research 12/2013; 20(3). DOI:10.1007/s12253-013-9724-z · 1.81 Impact Factor